Bright Ideas - CIN Feasibility Study

Status Recruiting

Clinical Trial Summary

In this study investigators will determine the feasibility of a future trial comparing chemotherapy-induced nausea control in children with ALL receiving oral 6-mercaptopurine who do and do not receive problem-solving skill training. This is a novel approach to controlling an important and common treatment-related symptom.

Clinical Trial Description

This study will evaluate a novel approach to controlling a treatment-related symptom that detracts significantly from the quality of life of many patients. It will preserve and enhance the patient's and family's autonomy with respect to self-care. If found to be effective, this approach may be generalizable to pediatric patients receiving chemotherapy other than 6-mercaptopurine and thus has the potential to improve the quality of life of many children receiving cancer therapy. This study will evaluate the efficacy of Bright IDEAS-CIN, adapted from the validated Bright IDEAS framework to improve CIN control in children with ALL who experience nausea while receiving 6-mercaptopurine. Bright IDEAS is an 8-session face-to-face intervention with a caregiver. In this first session, the caregiver is taught the problem-solving framework and begins working on their first self-selected problem. Sessions 2-7 involve working through relevant problems, with most caregivers working through 3-4 different problems. The final session summarizes the skills and discusses how to continue to use these new skills for new problems instead of lapsing into old ineffective strategies. Investigators adapted Bright IDEAS to meet the specific problem of CINV by adapting it to 3 sessions focused specifically on CINV, including the child in the conversation when developmentally appropriate and allowing the latter sessions to be conducted by phone or video-chat. ;

Study Design

Related Conditions & MeSH terms

Acute Lymphoblastic Leukemia (ALL)
Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trial Details

NCT number	NCT04929899
Study type	Interventional
Source	The Hospital for Sick Children
Contact	Lee Dupuis, PhD
Phone	416-813-7654
Email	lee.dupuis@sickkids.ca
Status	Recruiting
Phase	N/A
Start date	March 1, 2022
Completion date	June 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03590171` - International Study for Treatment of High Risk Childhood Relapsed ALL 2010	Phase 2
Terminated	`NCT02259348` - Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation	Phase 2
Recruiting	`NCT01351545` - A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Recruiting	`NCT02894645` - Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study	Phase 4
Completed	`NCT03236857` - A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies	Phase 1
Completed	`NCT03181126` - A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma	Phase 1
Recruiting	`NCT05291390` - Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)	Phase 2
Recruiting	`NCT01758042` - Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders	N/A
Completed	`NCT01282593` - Potential Role of CD9 and Implication of Motility Process in Pathogenesis of TEL/ALM1-positive ALL Relapses (LAL TEL/ALM1 and CD9).	N/A
Completed	`NCT01221857` - Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies	Phase 1/Phase 2
Completed	`NCT01885897` - IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT	Phase 1/Phase 2
Completed	`NCT03067584` - Genetic Study of Familial Acute Lymphoblastic Leukemia
Recruiting	`NCT05884333` - Cord Blood Transplant in Adults With Blood Cancers	Phase 2
Terminated	`NCT02338050` - Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation	Phase 2
Completed	`NCT01802814` - International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010	Phase 3
Completed	`NCT00495079` - Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia	Phase 2
Completed	`NCT01735955` - Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study	Phase 4
Terminated	`NCT01439347` - A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL	Phase 3
Active, not recruiting	`NCT02061800` - CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant	Phase 1/Phase 2
Terminated	`NCT01050764` - Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells	Phase 1/Phase 2